2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2402

Acoustic Emissions Generated By the Temporomandibular Joint of Patients with Juvenile Idiopathic Arthritis and Their Implication on Patient Assessment and Screening: A Pilot Study
Abstract Number: 84

ACPA-Positive Risk-RA Subject without Subclinical Arthritis Are in High Risk for Later Arthritis Onset, Especially Carriers of HLA-SE Risk-Gene
Abstract Number: 588

Acr Hybrid Analysis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Abstract Number: 2070

Activated Tendon Stromal Cells Drive a Type 17 Immune Response Via CCL20: A Potential Role in the Pathogenesis of Enthesitis in Psoriatic Arthritis
Abstract Number: 2233

Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis
Abstract Number: 672

Activation of NLRP3 Inflammasomes in Peripheral Blood Mononuclear Cells of Patients with Ankylosing Spondylitis
Abstract Number: 2109

Activation of T Follicular Helper Cells through Epigenetic Regulation By STAT1 and STAT4 in Lupus Patients
Abstract Number: 2680

Activation Towards Health Self-Management in Patients with Systemic Lupus Erythematosus
Abstract Number: 2199

Active Disease and Follow up 18f-FDG-PET/CT in Patients with Giant Cell Arteritis. Which Treatment Is More Likely to Achieve Remission?
Abstract Number: 1320

Activity Tracker Bracelets Captures Familial Mediterranean Fever Attacks and Their Impact on Daily Physical Activities
Abstract Number: 2571

Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1986

Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization
Abstract Number: 81

Additive Effects of Functional Rheumatoid Arthritis (RA) LBH Risk Alleles on LBH Gene Transcription
Abstract Number: 862

Addressing the Pediatric Rheumatology Workforce Shortage: Results from the American College of Rheumatology Annual Pediatric Residents Program
Abstract Number: 2800

Adenosine 2a Receptor Signals Act to Limit Autoimmune Arthritis By Inhibiting Pathogenic Germinal Center T Follicular Helper (GC-Tfh) Cells

« Previous Page
1
…
7
8
9
10
11
…
202
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].